CoChat
Sign Up
Cited by 67Hormonal and reproductive studiesSexual function and dysfunction studiesMenopause: Health Impacts and Treatments

Effect of Testosterone Treatment on Constitutional and Sexual Symptoms in Men With Type 2 Diabetes in a Randomized, Placebo-Controlled Clinical Trial

Gianatti, Emily J., Dupuis, Philippe, Hoermann, Rudolf, Zajac, Jeffrey D., Grossmann, Mathis·2014·The Journal of Clinical Endocrinology & Metabolism
DOI 10.1210/jc.2014-1872
Open this paper in CoChat — free account

Abstract

OBJECTIVE: The objective of the study was to assess the effect of T treatment on constitutional and sexual symptoms in men with type 2 diabetes (T2D). DESIGN: This was a randomized double-blind, parallel, placebo-controlled trial. SETTING: The study was conducted at a tertiary referral center. PATIENTS: Men aged 35-70 years with T2D, a hemoglobin A1c less than 8.5%, and a total T level less than 12.0 nmol/L (346 ng/dL) with mild to moderate aging male symptoms and erectile dysfunction. INTERVENTION: Eighty-eight participants were randomly assigned to 40 weeks of im T undecanoate (n = 45) or matching placebo (n = 43). MAIN OUTCOME MEASURES: Constitutional symptoms using the aging male symptoms (AMS) score, sexual desire (question 17 AMS score), and erectile function (International Index of Erectile Function-5). RESULTS: T treatment did not substantially improve aging male symptoms [mean adjusted difference (MAD) in change over 40 weeks across the T and placebo groups in AMS total score, -0.9 (95% confidence interval [CI] -4.1, 2.2), P = .67] or sexual desire [MAD in question 17 AMS, -0.3 (95% CI -0.8, 0.2), P = .17]. Although compared with placebo, erectile function in men assigned to T was reduced [MAD in International Index of Erectile Function abridged version 5, -2.0 (95% CI -3.4, -0.6), P < .02], there was no significant difference between baseline and 40-week International Index of Erectile Function abridged version 5 scores if both groups were analyzed separately. At baseline, symptoms were worse in men with depression and microvascular complications but did not correlate with T levels. CONCLUSIONS: In this trial, T treatment did not substantially improve constitutional or sexual symptoms in obese, aging men with T2D with mild to moderate symptoms and modest reduction in T levels typical for the vast majority of such men.

Integrity signals

Registry

Crossref · 10.1210/jc.2014-1872

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In an RCT in older men with long-standing diabetes (mean duration 8-9 years) and a high comorbid burden, testosterone treatment did not improve androgen deficiency-like symptoms or sexual function.

    “Interestingly, in an RCT using the same questionnaires as Ng Tang Fui's study, 91,101 but in a cohort of older men with long-standing diabetes (mean duration 8-9 years) and a high comorbid burden, testosterone treatment did not improve androgen deficiency-like symptoms or sexual function.105”

    From Hypogonadism and male obesity: Focus on unresolved questions (2018) · cites this paper as [105]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Gianatti, E. J., Dupuis, P., Hoermann, R., Zajac, J. D., & Grossmann, M.
Affiliations
The University of Melbourne (AU)
Corresponding author
Grossmann, Mathis
ORCID
Venue
The Journal of Clinical Endocrinology & Metabolism
Publisher
The Endocrine Society
Published
2014-10
Volume
99
Issue
10
Pages
3821-3828
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
DOI
10.1210/jc.2014-1872
OpenAlex
W2115164543
Cited by
67
References
29
Citations by year
2026: 1 · 2025: 2 · 2024: 5 · 2023: 5 · 2022: 5 · 2021: 3 · 2020: 4 · 2019: 7 · 2018: 5 · 2017: 10 · 2016: 7 · 2015: 9 · 2014: 4
FWCI
8.04
Type
journal article
Language
en
Open access
closed
Locations
  • The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
  • PubMed (publishedVersion)
  • Minerva Access (University of Melbourne) (submittedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
  • Health Sciences › Medicine › Psychiatry and Mental health › Sexual function and dysfunction studies
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
Keywords
testosterone replacement therapy, type 2 diabetes, aging male symptoms, erectile dysfunction, sexual desire, constitutional symptoms, male hypogonadism, depression, microvascular complications, obesity
MeSH terms
Adult, Aged, Aging, Androgens, Depression, Diabetes Mellitus, Type 2, Double-Blind Method, Humans, Erectile Dysfunction, Libido, Male, Middle Aged, Obesity, Placebos, Testosterone, Treatment Outcome, Hormone Replacement Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review